Neuromodulation : journal of the International Neuromodulation Society
-
We retrospectively investigated the correlation between disease duration and the therapeutic effect of globus pallidus internus (GPi) stimulation in patients with primary cervical dystonia (CD). ⋯ Bilateral GPi-DBS is an effective long-term therapy in patients with CD. The delivery of GPi stimulation in the earlier course of CD may yield greater postoperative improvement.
-
Letter Case Reports
Novel use of intrathecal baclofen drug delivery system for periodic focal dystonia in a teenager.
Focal dystonia, often affecting part of a limb, is a manifestation of complex regional pain syndrome (CRPS). This can be difficult to diagnose and treat. Furthermore, there may be significant latency between the onset of dystonia after the diagnosis of CRPS. We present the case of a 15-year-old girl with periodic focal dystonia who has been successfully treated with an intrathecal baclofen pump. ⋯ Intrathecal baclofen therapy can be effective in the management of focal dystonia after rigorous preoperative testing and counseling of adolescents with CRPS.
-
To quantify the overall and disaggregated societal costs of intrathecal drug delivery systems (IDDSs) in the treatment of pain and spasticity in the United States. ⋯ The societal costs for IDDS patients are high and extremely variable. A relatively small number of patients made an extreme number of medical encounters and represent a heavy societal cost burden. In order to reduce the growing societal cost of chronic pain and spasticity treatment, measures should be taken to reduce the resource utilization and costs of the most challenging patients.
-
Multicenter Study Clinical Trial
Subthalamic deep brain stimulation with a new device in Parkinson's disease: an open-label trial.
We aimed to evaluate the safety and efficacy of subthalamic nucleus deep brain stimulation (STN-DBS) with a new stimulator (Beijing PINS Medical Co., Ltd, PNS 1101) in Parkinson's disease (PD). ⋯ STN-DBS with the PINS device significantly improved the symptoms of PD when compared with baseline in this trial. This new device may be recommended for the treatment of patients with advanced PD; however, a randomized, double-blinding trial will be required.